Cargando...
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes
AIM: Taxanes are anti-cancer agents used to treat several types of solid tumours. They are metabolized by cytochrome P450 (CYP) 3A, displaying a large pharmacokinetic (PK) variability. In this study, we evaluated the endogenous CYP3A4 marker 4β-hydroxycholesterol (4β-OHC) as a potential individual t...
Guardado en:
| Publicado en: | Br J Clin Pharmacol |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley & Sons, Ltd
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4574840/ https://ncbi.nlm.nih.gov/pubmed/26119961 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12707 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|